IRADIMED Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

IRADIMED şirketinin toplam hissedar öz sermayesi $83.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $94.2M ve $10.8M dir. IRADIMED 'in FAVÖK'ü $21.3M faiz karşılama oranı -11.4 dur. Şirketin $51.7M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-11.4x
Nakit	US$51.72m
Eşitlik	US$83.43m
Toplam yükümlülükler	US$10.81m
Toplam varlıklar	US$94.25m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 46K 'nin kısa vadeli varlıkları ( $74.3M ) kısa vadeli yükümlülüklerini ( $8.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: 46K şirketinin kısa vadeli varlıkları ( $74.3M ) uzun vadeli yükümlülüklerini ( $2.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 46K borçsuzdur.

Borcun Azaltılması: 46K un 5 yıl önce borcu yoktu.

Borç Kapsamı: 46K un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 46K şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

IRADIMED Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Upcoming dividend of US$0.15 per share

Investor sentiment improves as stock rises 27%

Third quarter 2024 earnings released: EPS: US$0.40 (vs US$0.40 in 3Q 2023)

Iradimed Corporation Revises Earnings Guidance for the Year 2024

IRADIMED CORPORATION to Report Q3, 2024 Results on Oct 31, 2024

Upcoming dividend of US$0.15 per share

Second quarter 2024 earnings released: EPS: US$0.39 (vs US$0.33 in 2Q 2023)

IRADIMED CORPORATION Declares A Regular Quarterly Cash Dividend, Payable on August 30, 2024

IRADIMED CORPORATION to Report Q2, 2024 Results on Aug 01, 2024

Independent Director recently sold €78k worth of stock

IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend, Payable on May 30, 2024

IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024

IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: EPS: US$1.36 (vs US$1.02 in FY 2022)

IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024

IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024

IRadimed Corporation Approves Special Cash Dividend, Payable on January 12, 2024

Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023

IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023

IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023

IRadimed Corporation Revises Earnings Guidance for the Year 2023

Investor sentiment improves as stock rises 32%

Full year 2022 earnings released: EPS: US$1.02 (vs US$0.76 in FY 2021)

Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023

IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023

IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023

Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022

IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

IRadimed Corporation Announces Board Changes

Independent Director recently sold €113k worth of stock

Insufficient new directors

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.12 in 2Q 2021)

IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022

Insufficient new directors

IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022

Iradimed Corporation Revises Earnings Guidance for the Full Year 2022

IRadimed Corporation to Report Q1, 2022 Results on Apr 29, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

IRadimed Corporation Announces Special Share Cash Dividend, Payable on February 24, 2022

iRadimed Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2022

Independent Director recently sold €785k worth of stock

Second quarter 2021 earnings released: EPS US$0.12 (vs US$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.11 (vs US$0.15 in 1Q 2020)

IRadimed Corporation Provides Financial Guidance for Fiscal Year 2021

Full year 2020 earnings released

Revenue beats expectations

New 90-day high: €20.80

IRadimed Corporation to Report Q4, 2020 Results on Feb 04, 2021

New 90-day high: €19.70

Third quarter 2020 earnings released: EPS US$0.088

Revenue beats expectations

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

IRadimed Corporation to Report Q3, 2020 Results on Oct 30, 2020

IRadimed Corporation Withdraws Full-Year 2020 Financial Guidance and Not Providing Any Additional Financial Guidance

IRadimed Corporation to Report Q2, 2020 Results on Jul 30, 2020

IRadimed Corporation(NasdaqCM:IRMD) dropped from Russell 2000 Dynamic Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin